Literature DB >> 19193636

Comparing pooled peptides with intact protein for accessing cross-presentation pathways for protective CD8+ and CD4+ T cells.

Hongwei Zhang1, Hai Hong, Demin Li, Shiwu Ma, Ying Di, Adam Stoten, Neil Haig, Katalin Di Gleria, Zhanru Yu, Xiao-Ning Xu, Andrew McMichael, Shisong Jiang.   

Abstract

To better understand the mechanisms of intracellular trafficking and presentation of exogenous peptides by antigen-presenting cells (APC), we compared the handling of overlapping 24-mer peptides from HIV Nef either mixed or covalently linked in tandem in one protein. Once internalized, peptides trafficked not only to endosomes but also to cytosol, and activated CD8(+) and CD4(+) T cells. In contrast, whole protein was found to traffic only to the endosomal compartments, and primarily activated CD4(+) T cells. Finally, with adjuvant, overlapping peptides were capable of protecting against lethal viral challenge, whereas the intact protein was less protective. These data suggest that overlapping long peptides are cross-presented through more varied intracellular routes and are more efficient in priming protective immunity than the whole protein.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19193636      PMCID: PMC2666570          DOI: 10.1074/jbc.M809456200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  33 in total

Review 1.  The impact of the non-classical MHC proteins HLA-DM and HLA-DO on loading of MHC class II molecules.

Authors:  H Kropshofer; G J Hämmerling; A B Vogt
Journal:  Immunol Rev       Date:  1999-12       Impact factor: 12.988

2.  Friendly and dangerous signals: is the tissue in control?

Authors:  Polly Matzinger
Journal:  Nat Immunol       Date:  2007-01       Impact factor: 25.606

3.  Adjuvant-enhanced antibody responses in the absence of toll-like receptor signaling.

Authors:  Amanda L Gavin; Kasper Hoebe; Bao Duong; Takayuki Ota; Christopher Martin; Bruce Beutler; David Nemazee
Journal:  Science       Date:  2006-12-22       Impact factor: 47.728

4.  Activation of type B T cells after protein immunization reveals novel pathways of in vivo presentation of peptides.

Authors:  Scott B Lovitch; Thomas J Esparza; George Schweitzer; Jeremy Herzog; Emil R Unanue
Journal:  J Immunol       Date:  2007-01-01       Impact factor: 5.422

5.  Immunology: Toll-like receptors and antibody responses.

Authors:  D Nemazee; A Gavin; K Hoebe; B Beutler
Journal:  Nature       Date:  2006-05-18       Impact factor: 49.962

Review 6.  More than one reason to rethink the use of peptides in vaccine design.

Authors:  Anthony W Purcell; James McCluskey; Jamie Rossjohn
Journal:  Nat Rev Drug Discov       Date:  2007-05       Impact factor: 84.694

7.  Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows low toxicity and robust immunogenicity.

Authors:  Gemma G Kenter; Marij J P Welters; A Rob P M Valentijn; Margriet J G Lowik; Dorien M A Berends-van der Meer; Annelies P G Vloon; Jan W Drijfhout; Amon R Wafelman; Jaap Oostendorp; Gert Jan Fleuren; Rienk Offringa; Sjoerd H van der Burg; Cornelis J M Melief
Journal:  Clin Cancer Res       Date:  2008-01-01       Impact factor: 12.531

8.  Distinct uptake mechanisms but similar intracellular processing of two different toll-like receptor ligand-peptide conjugates in dendritic cells.

Authors:  Selina Khan; Martijn S Bijker; Jimmy J Weterings; Hans J Tanke; Gosse J Adema; Thorbald van Hall; Jan W Drijfhout; Cornelis J M Melief; Hermen S Overkleeft; Gijsbert A van der Marel; Dmitri V Filippov; Sjoerd H van der Burg; Ferry Ossendorp
Journal:  J Biol Chem       Date:  2007-04-26       Impact factor: 5.157

Review 9.  Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines.

Authors:  Cornelis J M Melief; Sjoerd H van der Burg
Journal:  Nat Rev Cancer       Date:  2008-05       Impact factor: 60.716

Review 10.  The many roads to cross-presentation.

Authors:  Tom A M Groothuis; Jacques Neefjes
Journal:  J Exp Med       Date:  2005-11-14       Impact factor: 14.307

View more
  38 in total

Review 1.  Cross-priming in health and disease.

Authors:  Christian Kurts; Bruce W S Robinson; Percy A Knolle
Journal:  Nat Rev Immunol       Date:  2010-06       Impact factor: 53.106

2.  Analysis of nucleophosmin-anaplastic lymphoma kinase (NPM-ALK)-reactive CD8(+) T cell responses in children with NPM-ALK(+) anaplastic large cell lymphoma.

Authors:  V K Singh; S Werner; H Hackstein; V Lennerz; A Reiter; T Wölfel; C Damm-Welk; W Woessmann
Journal:  Clin Exp Immunol       Date:  2016-08-16       Impact factor: 4.330

Review 3.  Engaging Natural Killer T Cells as 'Universal Helpers' for Vaccination.

Authors:  Mary Speir; Ian F Hermans; Robert Weinkove
Journal:  Drugs       Date:  2017-01       Impact factor: 9.546

4.  ML1419c peptide immunization induces Mycobacterium leprae-specific HLA-A*0201-restricted CTL in vivo with potential to kill live mycobacteria.

Authors:  Annemieke Geluk; Susan J F van den Eeden; Karin Dijkman; Louis Wilson; Hee Jin Kim; Kees L M C Franken; John S Spencer; Maria C V Pessolani; Geraldo M B Pereira; Tom H M Ottenhoff
Journal:  J Immunol       Date:  2011-06-24       Impact factor: 5.422

5.  Spatial separation of the processing and MHC class I loading compartments for cross-presentation of the tumor-associated antigen HER2/neu by human dendritic cells.

Authors:  Renato B Baleeiro; René Rietscher; Andrea Diedrich; Justyna A Czaplewska; Claus-Michael Lehr; Regina Scherließ; Andrea Hanefeld; Michael Gottschaldt; Peter Walden
Journal:  Oncoimmunology       Date:  2015-05-26       Impact factor: 8.110

Review 6.  Vaccines for established cancer: overcoming the challenges posed by immune evasion.

Authors:  Sjoerd H van der Burg; Ramon Arens; Ferry Ossendorp; Thorbald van Hall; Cornelis J M Melief
Journal:  Nat Rev Cancer       Date:  2016-03-11       Impact factor: 60.716

7.  Targeting self and neo-epitopes with a modular self-adjuvanting cancer vaccine.

Authors:  Elodie Belnoue; Jean-François Mayol; Susanna Carboni; Wilma Di Berardino Besson; Eloise Dupuychaffray; Annika Nelde; Stefan Stevanovic; Marie-Laure Santiago-Raber; Paul R Walker; Madiha Derouazi
Journal:  JCI Insight       Date:  2019-04-23

8.  Effects of Cross-Presentation, Antigen Processing, and Peptide Binding in HIV Evasion of T Cell Immunity.

Authors:  Blake F Frey; Jiansheng Jiang; Yongjun Sui; Lisa F Boyd; Bin Yu; Gwen Tatsuno; Rolf Billeskov; Shahram Solaymani-Mohammadi; Phillip W Berman; David H Margulies; Jay A Berzofsky
Journal:  J Immunol       Date:  2018-01-26       Impact factor: 5.422

Review 9.  Therapeutic cancer vaccines.

Authors:  Cornelis J M Melief; Thorbald van Hall; Ramon Arens; Ferry Ossendorp; Sjoerd H van der Burg
Journal:  J Clin Invest       Date:  2015-07-27       Impact factor: 14.808

Review 10.  Novel tumour antigens and the development of optimal vaccine design.

Authors:  Victoria A Brentville; Suha Atabani; Katherine Cook; Lindy G Durrant
Journal:  Ther Adv Vaccines Immunother       Date:  2018-04-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.